Drug
Double Blind Imsidolimab
Double Blind Imsidolimab: highest development phase Phase 3, developed by Vanda Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Vanda Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Double-blind 200 mg imsidolimab NCT05366855 | Phase 3 | Generalized Pustular Psoriasis |
Latest
No recent events.
Follow Double Blind Imsidolimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.